Atlas Brown Inc. reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 1.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 29,077 shares of the biopharmaceutical company’s stock after selling 535 shares during the period. Atlas Brown Inc.’s holdings in Pfizer were worth $887,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Northstar Group Inc. increased its stake in shares of Pfizer by 0.3% in the fourth quarter. Northstar Group Inc. now owns 10,573 shares of the biopharmaceutical company’s stock worth $341,000 after buying an additional 31 shares in the last quarter. Ronna Sue Cohen increased its stake in shares of Pfizer by 0.4% in the fourth quarter. Ronna Sue Cohen now owns 7,805 shares of the biopharmaceutical company’s stock worth $252,000 after buying an additional 33 shares in the last quarter. Financial Advisory Service Inc. increased its stake in shares of Pfizer by 0.3% in the fourth quarter. Financial Advisory Service Inc. now owns 19,550 shares of the biopharmaceutical company’s stock worth $631,000 after buying an additional 57 shares in the last quarter. OLD Second National Bank of Aurora increased its stake in shares of Pfizer by 0.4% in the fourth quarter. OLD Second National Bank of Aurora now owns 27,880 shares of the biopharmaceutical company’s stock worth $900,000 after buying an additional 104 shares in the last quarter. Finally, Taylor Wealth Management Partners increased its stake in shares of Pfizer by 4.3% in the fourth quarter. Taylor Wealth Management Partners now owns 2,555 shares of the biopharmaceutical company’s stock worth $82,000 after buying an additional 105 shares in the last quarter.

Shares of Pfizer Inc. (NYSE:PFE) opened at 30.17 on Tuesday. Pfizer Inc. has a 12 month low of $28.47 and a 12 month high of $36.46. The stock has a market cap of $186.24 billion and a price-to-earnings ratio of 22.65. The company has a 50-day moving average price of $31.50 and a 200-day moving average price of $33.04.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 2nd. Investors of record on Friday, February 5th will be paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 3.98%. This is a positive change from Pfizer’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, February 3rd.

PFE has been the subject of a number of analyst reports. Jefferies Group raised their price target on Pfizer to $48.00 and gave the stock a “buy” rating in a research report on Monday, December 7th. Vetr upgraded Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.47 target price for the company in a research report on Tuesday, October 6th. Cowen and Company upgraded Pfizer from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $25.00 to $43.00 in a research report on Tuesday, October 20th. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Monday, January 4th. Finally, Atlantic Securities started coverage on Pfizer in a research report on Friday, December 18th. They set an “overweight” rating and a $39.00 target price for the company. Five research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Pfizer currently has a consensus rating of “Buy” and an average target price of $39.78.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (NYSE:PFE), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

12 Month Chart for NYSE:PFE

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.